ArticleFrontiers in oncology2023

Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden.

Mengyao Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.